The American Pharmacists Association (APhA) has expressed strong disappointment following the December 5, 2025, vote by the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP). The committee decided to remove the universal recommendation for administering the hepatitis B vaccine at birth for infants born in the United States. This significant change reverses a public health measure that has successfully been in place since 1991.
The universal birth-dose recommendation has played a crucial role in reducing acute hepatitis B virus (HBV) infections among infants and young children. Since its implementation, the incidence of these infections has sharply decreased, preventing numerous children from becoming chronic carriers of the virus. The hepatitis B vaccine is recognized as safe, effective, and the most reliable means of preventing chronic HBV infection.
APhA highlights that infants born to mothers who are not HBV carriers remain at risk due to potential exposure from infected household members, caregivers, or even through shared personal items. It is this risk that underscores the necessity for universal vaccination at birth.
Brigid Groves, PharmD, MS, vice president of professional affairs at APhA, stated, “Pharmacists have a long history of helping to prevent disease transmission through vaccine recommendation and administration, including against hepatitis B. We remain steadfast in our commitment to protecting patients across their lifespan. The science is clear: the hepatitis B birth dose saves lives, and there is no new evidence to justify delaying or removing this critical protection.”
The consequences of HBV infection are severe. Infants who contract the virus have a 90% likelihood of becoming chronic carriers. Furthermore, one in four infants infected at birth will face death due to HBV-related liver failure or liver cancer. Young children who contract the virus have a 20% to 50% chance of developing a lifelong chronic infection. These outcomes, along with the intensive treatment they necessitate, are preventable through timely vaccination.
In light of these concerns, APhA is committed to preserving the integrity of the established, evidence-based childhood immunization schedule, which includes the hepatitis B birth dose. The organization also emphasizes the importance of hepatitis B vaccination for adults. ACIP continues to recommend the vaccine series for all adults aged 19 to 59, adults aged 60 and older with risk factors, and any adult who requests vaccination. Hepatitis B vaccines are widely regarded as safe, effective, and covered by insurance.
APhA intends to continue advocating for evidence-based immunization policies, ensuring the health and safety of patients and communities across the nation.
The American Pharmacists Association serves as the sole organization dedicated to advancing the pharmacy profession. Based in Washington, D.C., APhA supports pharmacists, student pharmacists, and pharmacy technicians in optimizing medication use and improving patient health outcomes. Through effective advocacy, education, and the dissemination of evidence, APhA fosters opportunities for members to connect and learn from each other. As a pivotal voice in the development of national guidelines, policies, and best practices, APhA plays a crucial role in advancing both the profession and patient care.
To learn more about their initiatives and resources, visit www.pharmacist.com.
